The OncoAlert🚨ROUND UP Covering April 12-18, 2024 OncoAlert

✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM 
https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0



✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial 
https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext



✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X



✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
https://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext



✅The Lancet Breast Cancer Commission
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext



✅Top advances of the year: Uterine cancer
https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321